ContraFect Corporation Stock price

Equities

CFRXQ

US2123264093

Biotechnology & Medical Research

Delayed OTC Markets 03:05:02 2024-03-27 pm EDT 5-day change 1st Jan Change
0.0222 USD -0.04% Intraday chart for ContraFect Corporation +19.25% -25.67%
Sales 2023 * - Sales 2024 * - Capitalization 238K
Net income 2023 * -23M Net income 2024 * -30M EV / Sales 2023 * -
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * -
P/E ratio 2023 *
-0.01 x
P/E ratio 2024 *
-0.01 x
Employees 23
Yield 2023 *
-
Yield 2024 *
-
Free-Float 99.98%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.04%
1 week+19.25%
Current month+0.90%
1 month-26.16%
3 months-23.37%
6 months-95.79%
Current year-25.67%
More quotes
1 week
0.02
Extreme 0.0204
0.02
1 month
0.01
Extreme 0.0111
0.03
Current year
0.01
Extreme 0.0111
0.04
1 year
0.01
Extreme 0.0111
3.95
3 years
0.01
Extreme 0.0111
398.49
5 years
0.01
Extreme 0.0111
1 071.92
10 years
0.01
Extreme 0.0111
4 992.00
More quotes
Date Price Change Volume
24-03-27 0.0222 -0.04% 16,379
24-03-26 0.0223 +9.33% 518
24-03-25 0.0204 -5.04% 12,430
24-03-21 0.0214 +14.65% 17,162
24-03-20 0.0187 -16.89% 43,332

Delayed Quote OTC Markets, March 27, 2024 at 03:05 pm EDT

More quotes
ContraFect Corporation is a clinical-stage biotechnology company. The Company is focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its lead DLA product candidate, exebacase (CF-301), is used for the treatment of methicillin-resistant S. aureus (MRSA) bloodstream infections (bacteremia), including right-sided endocarditis, when used in addition to standard-of-care (SOC) anti-staphylococcal antibiotics in adult patients. Its CF-301 is being studied in an ongoing Phase Ib/II study in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci. Its other product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumanni, and has demonstrated potent in vivo activity against these pathogens.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
  1. Stock
  2. Equities
  3. Stock ContraFect Corporation - OTC Markets